Content under review

We're updating this page following the publication of our new methods, processes and topic selection manuals. Our previous manuals still apply to evaluations that started before 1 February 2022. The new manuals apply to evaluations that began after this date.

Past appeals

TA ID Appraisal short title Appeal hearing date
TBC Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405] 11 May 2021
TBC Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945] 3 September 2020
TBC Afamelanotide for treating erythropoietic protoporphyria 30 July 2018
TA111 Alzheimer´s disease - donepezil, rivastigmine, galantamine and memantine (review) 13-14 August 2006
TA142 Anaemia (cancer-treatment induced) - Erythropoetin (alpha and beta) and darbepoetin 2 June 2006
TA143 Ankylosing spondylitis - adalimumab, etanercept & infliximab 31 March 2008
TA010 Asthma (children under 5) - inhaler devices 31 August 2000
TA138 Asthma (in adults) - corticosteroids 9 January 2008
TA038 Asthma (older children) - inhaler devices 13 February 2002
TA249 Atrial fibrillation - dabigatran etexilate 7 February 2012
TA098 Attention deficit hyperactivity disorder - Methylphenidate, atomoxetine and dexamfetamine (review) 25 September 2005
ID3735 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy 28 September 2021
TA006 Breast cancer - taxanes 3 May 2000
TA054 Breast cancer - vinorelbine 15 August 2002
TBC Breast cancer (advanced or metastatic) - lapatinib 8 June 2009
TBC Breast cancer (advanced or metastatic) - lapatinib (second appeal) 17 August 2010
TA107 Breast cancer (early) - trastuzumab 26 July 2006
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal 23 May 2011
TA006 Breast cancer - taxanes 14 June 2000
TA250 Breast cancer - eribulin 13 February 2012
TA350 Breast cancer (HER2 positive, unresectable) - trastuzumab emtansine (after trastuzumab & taxane)  13 October 2014
TA033 Colorectal cancer - Irinotecan, oxaliplatin and raltitrexed 23 May 2001
TA033 Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed 8 January 2002
TA307 Colorectal cancer (metastatic) – aflibercept  23 January 2014
TA118 Colorectal cancer (metastatic) - bevacizumab & cetuximab 27 November 2006
TA102 Conduct disorder in children - parent-training/education programmes 21 April 2006
TA152 Coronary artery stents - drug-eluting stents 14 April 2008
TA051 Depression and anxiety - computerised cognitive behaviour therapy (CCBT) 19 July 2002
TA097 Depression and anxiety - computerised cognitive behavioural therapy (CCBT)(review) 17 November 2005
TA151 (review TA57) Diabetes - insulin pump therapy (review) 16 May 2008
TA063 Diabetes (Type 2) - glitazones (review) 2 June 2003
TA459

Dupuytren's contracture - collagenase clostridium histolyticum

30 November 2015
TA007 Dyspepsia - proton pump inhibitors 29 June 2000
TA059 Electroconvulsive Therapy (ECT) 12 February 2003
TA076 Epilepsy (adults) - newer drugs 19 January 2004
TBC Erenumab for treating migraine 4 December 2019
TA067 Flu (prophylaxis) - amantadine and oseltamivir 19 December 2002
TA064 Growth hormone deficiency (adults) - human growth hormone 20 August 2002
TA064 Growth hormone deficiency (adults) - human growth hormone 3 July 2003
TA145 Head and neck cancer - cetuximab 22 August 2007
TA008 Hearing disability - hearing aids 21 July 2000
TA166 Hearing impairment - cochlear implants 26 November 2008
TA189 Hepatocellular carcinoma (advanced and metastatic)- sorafenib 26 February 2010
TA018 Hernia (inguinal) - laparoscopic surgery 7 December 2000
TA002 Hip disease - replacement prostheses 31 March 2000
TA164 Hyperuricaemia - febuxostat 29 October 2008
TA504

Idiopathic pulmonary fibrosis - pirfenidone

2 December 2016,
and 1 December 2017
TA501

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer

8 December 2017
TA482

Kidney transplantation (adults) - immunosuppressive therapy (review)

30 March 2016
TA482

Kidney transplantation (children, adolescents) - immunosuppressive regimens (review)

30 March 2016
TA541 Leukaemia (acute lymphoblastic, relapsed, adults) - inotuzumab ozogamicen 3 November 2017
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab 25 May 2010
TA251 Leukaemia (chronic myeloid) - dastatinib, nilotinib, imatinib (intolerant, resistant) (including partial review of TA70) 4 November 2011
TA162 Lung cancer (non-small cell) - Erlotonib 6 June 2007
TA227 Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib: appeal 16 May 2011
TA124 Lung cancer (non-small cell) - pemetrexed 6 June 2007
TBC Lysosomal acid lipase deficiency - sebelipase alfa 25 April 2017
TA068 Macular degeneration (age-related) - photodynamic therapy 17 March 2003
TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib 30 June 2008
TA237 Macular oedema (diabetic) - ranibizumab: appeal 4 October 2011
TA078 Menorrhagia - endometrial ablation 26 January 2004
TA135 Mesothelioma - Pemetrexed disodium 27 October 2006
TA020 Motor neurone disease - riluzole 4 January 2001
TA129 Multiple myeloma - Bortezomib 8 February 2007
TA228 Multiple myeloma (first line) - bortezomib and thalidomide 15 November 2010
TA032 Multiple sclerosis - beta interferon and glatiramer 22-23 September 2000
TA032 Multiple sclerosis - beta interferon and glatiramer acetate 26 November 2001
TA218 Myelodysplastic syndrome - azacitidine 1 June 2010
TBC Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) 30 September 2016
TA494 Obesity (prolonged-release) - naltrexone-bupropion 12 December 2017
TA621 Osimertinib for untreated EGFR-positive non-small-cell lung cancer 30 September 2019
TA027 Osteoarthritis and rheumatoid arthritis - cox II inhibitors 7 June 2001
TA160 Osteoporosis - primary prevention 22 October 2007
TA160 Osteoporosis - primary prevention 15 September 2008
TA087 Osteoporosis - secondary prevention 22 October 2004
TA161 Osteoporosis - secondary prevention including strontium ranelate 22 October 2007
TA161 Osteoporosis - secondary prevention including strontium ranelate 15 September 2008
TA055 Ovarian cancer - paclitaxel (review) 12 November 2002
TA389 Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468] 24 April 2015
TA360 Pancreatic adenocarcinoma (Metastatic) paclitaxel albumin-bound nanoparticles (with gemcitabine, 1st line) [ID680] 16 March 2015
TBC Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536] 23 June 2020
TA135 Pemetrexed disodium for the treatment of malignant pleural mesothelioma (2) 23 November 2007
TA103 Psoriasis - efalizumab and etanercept 27 January 2006
TA104 Psoriatic arthritis - etanercept and infliximab 20 February 2006
TA104 Psoriatic arthritis (active) - apremilast (after-DMARDs) 6 November 2015
TA255 Prostate cancer - cabazitaxel 22 March 2012
TA352 Prostate cancer (advanced, hormone dependent) - degarelix depot [ID590] 12 November 2014
TA178 Renal cell carcinoma - bevacizumab, sorafenib, sunitinib and temsirolimus 13 July 2009
TA333 Renal cell carcinoma, locally advanced and/or metastatic (2nd line) - axitinib [ID518] 10 June 2013
TA219 Renal cell carcinoma (second line metastatic) - everolimus 28 February 2011
TA085 Renal transplantation - immuno-suppressive regimens (adults) 26 April 2004
TA130 Rheumatoid arthritis - Adalimumab, etanercept and infliximab 4 April 2007
TA219 Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) appeal decision 29 September 2008
TA072 Rheumatoid arthritis - anakinra 18 September 2003
TA375 Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537] 26 November 2015
TA141 Rheumatoid arthritis (refractory) - abatacept 17 March 2008
TA037 Rituximab for follicular lymphoma 21 May 2001
TA043 Schizophrenia - Atypical antipsychotic 24 April 2002
TA397 Systemic lupus erythematosus (active) - belimumab 18 July 2012
TA696 Tafamidis for treating transthyretin amyloid cardiomyopathy 4-5 March 2021
TA272 Transitional cell carcinoma of the urothelial tract - vinflunine 23 May 2011
TA090 Vascular disease - clopidogrel and dipyridamole 25 February 2005

Back to top

Rejected appeals

TA ID Appraisal Short title
TA201 Asthma (in children) - omalizumab
TA265 Bone metastases from solid tumours - denosumab
TA566 Cochlear implant for children and adults with severe to profound deafness (Part review of TA166) [ID1469]
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (review)
TA510 Multiple myeloma (relapsed, refractory) - daratumumab (after proteasome inhibitor and immunomodulatory agent)
GID-HST10008 Neuronal ceroid lipofuscinosis type 2 - cerliponase alfa (Biomarin) [ID943]
TA316 Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel)
TA272 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine

Back to top

Cancelled appeals

TA ID Appraisal short title
TA383 Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) - adalimumab, certolizumab pegol, etanercept, golimumab and infliximab (inc rev TA143 and TA233) ID694
HST6

Hypophosphatasia (paediatric-onset) - asfotase alfa

TA309 Lung cancer (non small cell, non squamous) - pemetrexed (maintenance following pemetrexed & cisplatin)
TBC Metreleptin for treating lipodystrophy
TBC Non-small cell lung cancer (non-squamous) - nivolumab (CDF review TA484) [ID1572]

Back to top